## Chronic Lithium Toxicity: Nephrogenic Diabetes Insipidus ### Clinical Presentation This patient exhibits **chronic lithium-induced nephrogenic diabetes insipidus (NDI)**: - **Polyuria & polydipsia** — hallmark of NDI - **Low urine specific gravity** (1.008, normal >1.010) — inability to concentrate urine - **Mild renal impairment** — creatinine 1.3 (baseline 0.8), indicating chronic lithium nephrotoxicity - **Cognitive changes** — forgetfulness may reflect chronic lithium effects or dehydration - **Serum lithium level therapeutic** (0.9 mEq/L) — toxicity is not acute but chronic/cumulative ### Pathophysiology of Lithium-Induced NDI ```mermaid flowchart TD A[Chronic Lithium Exposure]:::outcome --> B[Accumulation in Collecting Duct Cells]:::action B --> C[Inhibition of Adenylyl Cyclase]:::action C --> D[Reduced cAMP Production]:::action D --> E[Decreased Aquaporin-2 Water Channel Expression]:::action E --> F[Impaired Water Reabsorption]:::outcome F --> G[Nephrogenic Diabetes Insipidus]:::urgent G --> H[Polyuria, Polydipsia, Dehydration]:::urgent ``` ### Diagnostic Approach **High-Yield:** - **Water deprivation test:** distinguishes central DI (urine osmolality rises with desmopressin) from nephrogenic DI (urine osmolality does NOT rise with desmopressin) - In lithium-induced NDI: urine osmolality remains low (<300 mOsm/kg) even after water deprivation and desmopressin challenge - Serum osmolality is normal or low-normal (295 mOsm/kg here) because of compensatory polydipsia **Key Point:** - Lithium-induced NDI occurs in 20–40% of chronic lithium users - It is **partially reversible** if lithium is discontinued early; becomes irreversible after prolonged exposure (>10 years) - Mechanism: lithium blocks the coupling of V2 vasopressin receptors to G-proteins, reducing cAMP ### Management Options | Intervention | Rationale | Efficacy | |---|---|---| | **Switch mood stabilizer** | Removes lithium; allows NDI recovery if caught early | Best if <5 yrs exposure | | **Add amiloride** | ENaC blocker; reduces lithium entry into collecting duct cells | 50–70% reduce polyuria | | **Add thiazide diuretic** | Paradoxically reduces urine output in NDI (volume depletion → enhanced proximal reabsorption) | Adjunctive only | | **Increase fluid intake** | Symptomatic relief only; does not treat underlying mechanism | Temporary | | **Continue lithium without intervention** | Allows progressive renal damage | NOT appropriate | **Clinical Pearl:** - **Amiloride is preferred** if lithium must be continued (e.g., excellent mood control, no alternative tolerated): blocks lithium entry via ENaC in collecting duct - **Switching to divalproex, lamotrigine, or quetiapine** is appropriate if NDI is severe or if renal function is declining ### Correct Management Sequence 1. **Confirm diagnosis:** water deprivation test + desmopressin challenge 2. **Assess reversibility:** duration of lithium use, degree of renal impairment 3. **Decide:** - If <5 years exposure and significant NDI → consider switching mood stabilizer - If excellent mood control and willing to tolerate NDI → add amiloride ± thiazide - If renal function declining → discontinue lithium ### Why NOT the Other Options **Option 0 (Continue without intervention):** - Progressive polyuria and polydipsia impair quality of life - Chronic dehydration increases risk of acute lithium toxicity - Renal function may continue to decline **Option 2 (Increase lithium dose):** - Would worsen NDI and accelerate renal damage - Cognitive impairment is NOT improved by higher lithium levels - Dangerous approach **Option 3 (Immediate discontinuation + divalproex):** - Premature without confirming NDI diagnosis - Divalproex has its own side effects (weight gain, hepatotoxicity risk, teratogenicity) - Should be considered only after diagnostic confirmation and risk–benefit discussion [cite:Kaplan & Sadock's Synopsis of Psychiatry 11e Ch 31; Harrison 21e Ch 397]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.